GlassScriptPhysician profile
Keanan Thomas Dowell
NPI 1730745167
$1,616.91
in general payments reported to CMS, 2019-2025
24 companies · $602 in 2025
The $602 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $325 · 2024: $690 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.94 |
| Education | $266.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $365.31 | 2023-2025 | Jakafi, Monjuvi |
| Pfizer INC. | $280.41 | 2023-2025 | |
| Janssen Biotech, INC. | $144.50 | 2024-2025 | Darzalex, Erleada, Talvey |
| Genzyme Corporation | $128.25 | 2023-2025 | |
| Daiichi Sankyo INC. | $73.75 | 2024-2025 | Enhertu, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $70.86 | 2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $56.96 | 2025 | Iclusig, Livtencity |
| Merck Sharp & Dohme LLC | $51.76 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Lilly USA, LLC | $47.24 | 2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $38.45 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $34.73 | 2024 | Xtandi |
| Genentech USA, INC. | $34.29 | 2024 | Phesgo, Perjeta |
| Abbvie INC. | $32.70 | 2025 | |
| Deciphera Pharmaceuticals INC. | $32.46 | 2025 | |
| Beigene USA, INC. | $28.89 | 2025 | Brukinsa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $26.67 | 2025 | Cosela |
| Beone Medicines USA, INC. | $25.86 | 2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $25.78 | 2024 | Orgovyx |
| Kite Pharma, INC. | $23.97 | 2024 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.48 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.23 | 2025 | Libtayo |
| Tempus Ai, INC | $20.00 | 2025 | Xt Cdx |
| Sobi, INC | $15.82 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keanan Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.